fluticasone furoate/vilanterol vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Reported efficacy
Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)
Result source: NCT01086384
Vilanterol
Developed by GlaxoSmithKline
NCT00381667 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.
Reported efficacy
Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)
Result source: NCT00600171
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | Vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT05757102 | —Not reported |
| Trough FEV1, change | 0.4 vs 0.2+0.2 vs placeboNCT011651388 other results
| 0.3 vs 0.1+0.1 vs placeboNCT006001718 other results
|
| ACQ-5, change | -1.2 vs -1.1vs FFNCT032481281 other result
| —Not reported |
| OCS dose reduction | —Trial running · NCT05757102 | —Not reported |
Severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Vilanterol
- —Not reported
Trough FEV1, change
- fluticasone furoate/vilanterol
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
8 other results
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- 0.3 vs 0.3 NCT01147848
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT03248128
- -0.1 vs -0.1 NCT02094937
- 0.3 vs 0.2 NCT03248128
- Vilanterol
- 0.3 vs 0.1+0.1 vs placeboNCT00600171
8 other results
- 0.3 vs 0.1 NCT00600171
- 0.3 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- -0.5 vs -0.8 NCT01128569
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- fluticasone furoate/vilanterol
- -1.2 vs -1.1vs FFNCT03248128
1 other result
- -1.3 vs -1.1 NCT03248128
- Vilanterol
- —Not reported
OCS dose reduction
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Vilanterol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. fluticasone furoate/vilanterol: 14 of 14 rows · Vilanterol: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/vilanterol Rows use multiple source trials | Vilanterol Rows use multiple source trials |
|---|---|---|
| Evening PEF absolute change · L/min | 26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODa,b,c,d NCT01165138 · Phase 3 2 other source trials39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD NCT01686633 · Phase 3 41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD NCT01686633 · Phase 3 | 34 vs 0.4 placebo L/min25 µge,a,b,c,d NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 4 more doses38.4 vs 0.4 placebo L/min50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 28.9 vs 0.4 placebo L/min12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 24.5 vs 0.4 placebo L/min6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 14 vs 0.4 placebo L/min3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 |
| Evening PEF Change L/Min absolute change · L/min | 5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b,c,f NCT02301975 · Phase 3 · registry result, not featured evidence | 220.3 vs 215.9 placebo L/min @ 4wk25 µg ODe,a,b,c,f NCT01573767 · Phase 2 · registry result, not featured evidence show 5 more doses11.1 vs 5.9 placebo L/min @ 4wk25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 222.4 vs 215.9 placebo L/min @ 4wk12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 13.7 vs 5.9 placebo L/min @ 4wk12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 221.4 vs 215.9 placebo L/min @ 4wk6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 9.4 vs 5.9 placebo L/min @ 4wk6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence |
| FEV1 absolute change · L | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b,c,g NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence | -0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODa,b,c,g NCT01128569 · Phase 2 · registry result, not featured evidence |
| FEV1 AUC0-24 absolute change · L | 0.341 vs 0.377 Fluticasone Propionate/Salmeterol L @ 24wk100/25 µg ODa,h,c,f NCT01147848 · Phase 3 · Asthma · phase 3 | 0.315 vs 0.149 placebo L @ 4wk25 µge,a,h,c,f NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 4 more doses0.321 vs 0.149 placebo L @ 4wk50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.292 vs 0.149 placebo L @ 4wk12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.253 vs 0.149 placebo L @ 4wk6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.3 vs 0.149 placebo L @ 4wk3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 |
| FEV1 Wm0 24 h absolute change · L | 0.513 vs 0.212 placebo L @ 12wk100/25 µg ODb,c NCT01165138 · Phase 3 2 other source trials0.474 vs 0.366 FF L @ 12wk100/25 µg OD NCT01686633 · Phase 3 0.499 vs 0.366 FF L @ 12wk200/25 µg OD NCT01686633 · Phase 3 | 0.359 vs 0.289 placebo L @ 12wk25 µg ODb,c NCT01181895 · Phase 3 · registry result, not featured evidence |
| Morning PEF absolute change · L/min | 14.9 vs 9.3 FF L/min @ 12wke,a,i,c,d NCT03248128 · Phase 3 · Asthma · phase 3 show 1 more dose11.9 vs 8.9 FF L/min @ 12wk NCT03248128 · Phase 3 · Asthma · phase 3 | 38.1 vs 1.9 placebo L/min25 µge,a,i,c,d NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 4 more doses44 vs 1.9 placebo L/min50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 34.2 vs 1.9 placebo L/min12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 26.8 vs 1.9 placebo L/min6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 18.7 vs 1.9 placebo L/min3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 |
| Rescue-free 24 h Periods absolute change · percentage points | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b,c,d NCT02094937 · Phase 3 · registry result, not featured evidence | 43.4% (n=101) vs 15% (n=99) placebo25 µge,a,b,c,d NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 4 more doses34% (n=102) vs 15% (n=99) placebo50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 29.6% (n=98) vs 15% (n=99) placebo12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 27.3% (n=101) vs 15% (n=99) placebo6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 25.8% (n=99) vs 15% (n=99) placebo3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 |
| Rescue-free 24-h Period percent change · % of baseline | 37.1% (n=201) vs 17.8% (n=202) placebo @ 12wk100/25 µg ODb,c NCT01165138 · Phase 3 3 other source trials34.8% (n=345) vs 22.6% (n=346) FF @ 12wk100/25 µg OD NCT01686633 · Phase 3 35.8% (n=346) vs 22.6% (n=346) FF @ 12wk200/25 µg OD NCT01686633 · Phase 3 30.1% (n=153) vs 8.3% (n=154) placebo @ 12wk100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence | 21.7% (n=115) vs 14.6% (n=115) placebo @ 12wk25 µg ODb,c NCT01181895 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24 h Periods absolute change · percentage points | -3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b,c,d NCT02301975 · Phase 3 · registry result, not featured evidence | 36.4% (n=101) vs 14.2% (n=98) placebo25 µge,a,b,c,d NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 4 more doses32.3% (n=102) vs 14.2% (n=98) placebo50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 26.8% (n=98) vs 14.2% (n=98) placebo12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 23.6% (n=101) vs 14.2% (n=98) placebo6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 22.6% (n=99) vs 14.2% (n=98) placebo3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 |
| Symptom-free 24-h Period percent change · % of baseline | 32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg ODb,c NCT01165138 · Phase 3 3 other source trials27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD NCT01686633 · Phase 3 29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD NCT01686633 · Phase 3 24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence | 19.4% (n=115) vs 12.7% (n=115) placebo @ 12wk25 µg ODb,c NCT01181895 · Phase 3 · registry result, not featured evidence |
| Dropout rate | —100/25 µgj NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 7.2%200/25 µg OD NCT01686633 · Phase 3 9.2%100/25 µg OD NCT01686633 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 14.4%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 12.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 7.9%25 µgk NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results4.9%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 9.9%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 16.8%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.2%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100/25 µgj NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 1%100/25 µg OD NCT01165138 · Phase 3 0.9%200/25 µg OD NCT01686633 · Phase 3 0.9%100/25 µg OD NCT01686633 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 2.6%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 1.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 1%25 µgk NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 1%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.1%100/25 µgj NCT01086384 · Phase 3 show 16 more results0.5%200/25 µg OD NCT01018186 · Phase 3 1.5%100/25 µg OD NCT01018186 · Phase 3 1.1% NCT03248128 · Phase 3 · Asthma · phase 3 0%100/25 µg OD NCT01165138 · Phase 3 0.3%200/25 µg OD NCT01686633 · Phase 3 1.2%100/25 µg OD NCT01686633 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1%100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 1.4%100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 1.3%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 0.6%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 0%25 µgk NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%25 µg NCT01453296 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100/25 µgj headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 show 15 more results200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 nasopharyngitis 10.4% upper respiratory tract infection 7% rhinitis allergic 4.2% NCT03248128 · Phase 3 · Asthma · phase 3 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100/25 µg OD nasopharyngitis 11.4% headache 8.4% upper respiratory tract infection 6.2% NCT01147848 · Phase 3 · Asthma · phase 3 100/25 µg QD upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 100/25 µg Once Daily upper respiratory tract infection 7.2% (placebo 9.1%) headache 4.6% (placebo 1.9%) nasopharyngitis 4.6% (placebo 8.4%) NCT01498679 · Phase 3 · registry result, not featured evidence 200/25 µg Once Daily upper respiratory tract infection 8.4% nasopharyngitis 3.9% rhinitis allergic 3.2% NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence | 25 µgk headache 6.9% (placebo 7.8%) upper respiratory tract infection 2% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 13 more results50 µg headache 7.8% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.5 µg headache 9% (placebo 7.8%) upper respiratory tract infection 3% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 6.25 µg headache 6.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 1% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 3 µg headache 11.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 25 µg OD headache 8.7% (placebo 4.3%) nasopharyngitis 7.8% (placebo 10.3%) oropharyngeal pain 5.2% (placebo 6%) NCT01181895 · Phase 3 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100/25 µg AM headache 25% (placebo 26.1%) nasopharyngitis 12.5% (placebo 13%) dysmenorrhoea 4.2% (placebo 0%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg PM headache 32% (placebo 26.1%) gastroenteritis 8% (placebo 0%) nasopharyngitis 8% (placebo 13%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 25 µg upper respiratory tract infection 11.1% (placebo 0%) headache 7.4% (placebo 7.7%) pyrexia 7.4% (placebo 0%) NCT01453296 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 4 weeks versus 24 weeks.
- gAssessment timepoints differ: 4.14 weeks versus 24 weeks.
- hPopulation context differs: baseline_threshold differs (fev1_pct_predicted>=40 versus fev1_pct_predicted<=85, fev1_pct_predicted>=40); prior_therapy differs (experienced versus none recorded).
- iPopulation context differs: age eligibility differs (adolescents and adults versus includes children); baseline_threshold differs (fev1_pct_predicted>=40 versus fev1_pct_predicted<=90, fev1_pct_predicted>50).
- jPopulation comparability has not been reviewed for 13 of these studies.
- kPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/vilanterol
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
Vilanterol
show 5 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Vilanterol's landscape